The prognostic value of CD44 expression in gastric cancer: A meta-Analysis

Biomedicine and Pharmacotherapy

Volumn 68, Issue 6, 2014, Pages 693-697

  Chen, Yansu ^a   Fu, Ziyi ^b   Xu, Sujuan ^c   Xu, Ye ^c   Xu, Pengfei ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CD44; Gastric cancer; Hazard ratios; Prognosis

Indexed keywords

CD44V5 ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SEX; STOMACH CANCER; SURVIVAL RATE; TUMOR INVASION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; MORTALITY; PROGNOSIS; STOMACH NEOPLASMS; TRENDS;

ANTIGENS, CD44; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908073175     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.08.001     Document Type: Article

References (43)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ajani J.A. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 2008, 6:813-814.
3. Goscinski M.A., Larsen S.G., Warloe T., Stoldt S., Nesland J.M., et al. Adenocarcinomas on the rise-does it influence survival from oesophageal cancer?. Scand J Surg 2009, 98:214-220.
4. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010, 17:3077-3079.
5. Lim L., Michael M., Mann G.B., Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol 2005, 23:6220-6232.
6. Naor D., Sionov R.V., Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997, 71:241-319.
7. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
8. Nagano O., Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004, 95:930-935.
9. Tulsyan S., Agarwal G., Lal P., Agrawal S., Mittal R.D., et al. CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population. PLoS One 2013, 8:e71073.
10. Doventas A., Bilici A., Demirell F., Ersoy G., Turna H., et al. Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepatogastroenterology 2012, 59:2196-2201.
11. Fang Y.J., Zhang L., Wu X.J., Lu Z.H., Li J.B., et al. Impact of ERbeta and CD44 expression on the prognosis of patients with stage II colon cancer. Tumour Biol 2012, 33:1907-1914.
12. Mayer B., Jauch K.W., Gunthert U., Figdor C.G., Schildberg F.W., et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993, 342:1019-1022.
13. Setala L., Lipponen P., Tammi R., Tammi M., Eskelinen M., et al. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology 2001, 138:13-20.
14. Chen S., Hou J.H., Feng X.Y., Zhang X.S., Zhou Z.W., et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Surg Oncol 2013, 107:799-806.
15. Hong R.L., Lee W.J., Shun C.T., Chu J.S., Chen Y.C. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 1995, 52:334-339.
16. Xie J.W., Huang C.M., Zheng C.H., Li P., Wang J.B., et al. Expression tumor stem cell surface marker CD44 in gastric cancer and its significance. Zhonghua Wei Chang Wai Ke Za Zhi 2013, 16:1107-1112.
17. Chen Y., Huang Y., Huang Y., Chen J., Wang S., et al. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One 2013, 8:e71140.
18. Yoo C.H., Noh S.H., Kim H., Lee H.Y., Min J.S. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. J Surg Oncol 1999, 71:22-28.
19. Jung W.Y., Kang Y., Lee H., Mok Y.J., Kim H.K., et al. Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma. Histopathology 2013, 63(4):474-481.
20. Shi J., Yao D., Liu W., Wang N., Lv H., et al. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 2012, 13:4714-4726.
21. Wakamatsu Y., Sakamoto N., Oo H.Z., Naito Y., Uraoka N., et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012, 62:112-119.
22. Ghaffarzadehgan K., Jafarzadeh M., Raziee H.R., Sima H.R., Esmaili-Shandiz E., et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008, 14:6376-6381.
23. Horikawa M., Iinuma H., Inoue T., Ogawa E., Fukushima R. Clinical significance of intraperitoneal CD44 mRNA levels of magnetically separated CD45-negative EpCAM-positive cells for peritoneal recurrence and prognosis in stage II and III gastric cancer patients. Oncol Rep 2011, 25:1413-1420.
24. Wang T., Ong C.W., Shi J., Srivastava S., Yan B., et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer 2011, 105:658-665.
25. Muller W., Schneiders A., Heider K.H., Meier S., Hommel G., et al. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997, 183:222-227.
26. Yamamichi K., Uehara Y., Kitamura N., Nakane Y., Hioki K. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 1998, 79:256-262.
27. Yamaguchi A., Goi T., Yu J., Hirono Y., Ishida M., et al. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol 2002, 79:230-235.
28. Zhou D.H., Ma Z.M., Chen Y. Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2007, 29:833-837.
29. Saito H., Tsujitani S., Katano K., Ikeguchi M., Maeta M., et al. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998, 83:1094-1101.
30. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
31. Wagner A.D., Unverzagt S., Grothe W., Kleber G., Grothey A., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010, 17(3):CD004064.
32. Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1-9.
33. Stock M., Otto F. Gene deregulation in gastric cancer. Gene 2005, 360:1-19.
34. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010, 46:1271-1277.
35. Wibulswas A., Croft D., Pitsillides A.A., Bacarese-Hamilton I., McIntyre P., et al. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002, 46:2059-2064.
36. Liu J., Xiao Z., Wong S.K., Tin V.P., Ho K.Y., et al. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget 2013, 4:1698-1711.
37. Palyi-Krekk Z., Barok M., Isola J., Tammi M., Szollosi J., et al. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007, 43:2423-2433.
38. Hu Z., Gao J., Zhang D., Liu Q., Yan L., et al. High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One 2013, 8:e57250.
39. Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009, 656:85-106.
40. Chai L., Liu H., Zhang Z., Wang F., Wang Q., et al. CD44 expression is predictive of poor prognosis in pharyngolaryngeal cancer: systematic review and meta-analysis. Tohoku J Exp Med 2014, 232:9-19.
41. Chen J., Zhou J., Lu J., Xiong H., Shi X., et al. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 2014, 14:15.
42. Jiang H., Zhao W., Shao W. Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis. Tumour Biol 2014.
43. Chen J., Li T., Liu Q., Jiao H., Yang W., et al. Clinical and prognostic significance of HIF-1alpha, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One 2014, 9:e91842.